KBioLab
- Company typePrivate
- Founded2016
- HeadquartersDaejeon, South Korea
- Headcount—
- GTM typeB2B
- OfferingServices
KBioLab firmographics
Firmographics- Name
- KBioLab
- Website
- https://kbiolab.co.kr
- Company type
- Private
- Founded year
- 2016
- Operating status
- Closed
- Ownership category
- akta.pro rank
KBioLab industry classification
Industry- Product category
- Microbiome Biotechnology
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Live Biotherapeutic Products (LBPs) (HLAAAFAA)
- akta.pro secondary industry
- Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery) (HLAAAFAJ)
Keywords
Where KBioLab is headquartered
LocationHeadquarters
- HQ city
- Daejeon
- HQ country
- South Korea
- HQ region
- Asia
Markets served
KBioLab business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations
KBioLab product offering
Product offeringCore offering
KBioLab is a biotechnology company that develops microorganism-based solutions aimed at building healthy lives. The company works with beneficial microorganisms in the health/life sciences space, but specific products, services, and applications are not disclosed in the available sources because the company website is offline.
Product overview
No product information available. The KBioLab website (kbiolab.co.kr) is currently offline due to expired hosting, displaying only a site expiration notice and admin login portal.
Differentiator
Problem solved
Functional benefit
Companies that use KBioLab
Customer profileIdeal customer profiles1 record
KBioLab technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
KBioLab partnerships and signals
Strategic signalRecent moves2 records
KBioLab competitors and assessment
Company assessmentDirect peers
- Genome & Company: Korean biotech developing microbiome-based therapeutics for oncology and immunology; comparable as a Korean-headquartered microbiome drug developer with clinical-stage assets.
- Vedanta Biosciences: US-based clinical-stage company developing defined consortia of live bacteria as therapeutics—directly comparable product category and mechanism to KBioLab's microbiome orientation.
- 4D Pharma: UK-based live biotherapeutic company developing single-strain microbiome therapeutics; comparable product modality and therapeutic category.
- KoBioLabs: Korean microbiome company developing live biotherapeutic products and microbiome-based interventions—directly comparable in geography, category, and stage orientation to KBioLab.
- LISCure Biosciences: Korean microbiome therapeutics company focused on live biotherapeutic products for metabolic and immune diseases—directly overlapping with KBioLab's stated microorganism-based health mission.
Broad incumbents
- Yakult Honsha: Global leader in probiotic/microbiome consumer health products; comparable as a microorganism-based health company, though operating at consumer-product scale rather than therapeutic.
- CJ Bioscience: Subsidiary of CJ Group focused on microbiome-derived therapies and diagnostics; a larger, well-capitalized Korean player operating in the same microbiome category as KBioLab.
- Seres Therapeutics: Clinical-stage US microbiome therapeutics company and one of the category leaders; comparable as a pioneer in defined live biotherapeutic products targeting serious diseases.
- Ferring Pharmaceuticals: Global pharma company with a dedicated microbiome therapeutics unit (Rebyota) and broad partnerships in the category; a comparable large incumbent pursuing the same therapeutic microbiome opportunity.
Emerging players
- Second Genome: Microbiome drug discovery platform identifying microbial metabolites for therapeutic use; comparable as a microbiome-focused biotech with a similar therapeutic-orientation.
Market position
Strengths2 records
Weaknesses3 records
Competitive moat1 record
Key risks6 records
Key highlights4 records
Customer concentration
KBioLab financial estimates
Financial estimateRevenue estimate
Valuation estimate
KBioLab leadership team
Management profileNumber of profiles
KBioLab funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
KBioLab M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about KBioLab
What does KBioLab do?
KBioLab is a biotechnology company that develops microorganism-based solutions aimed at building healthy lives. The company works with beneficial microorganisms in the health/life sciences space, but specific products, services, and applications are not disclosed in the available sources because the company website is offline.
When was KBioLab founded?
KBioLab was founded in 2016.
Where is KBioLab based?
KBioLab is headquartered in Daejeon, South Korea, in the Asia region.
Who are KBioLab's main competitors?
Direct peers on record are Genome & Company, Vedanta Biosciences, 4D Pharma, KoBioLabs and LISCure Biosciences. Broad incumbents are Yakult Honsha, CJ Bioscience, Seres Therapeutics and Ferring Pharmaceuticals. Second Genome is listed as an emerging player.
Does KBioLab have an API?
No public API is recorded for KBioLab.
What industry is KBioLab in?
KBioLab's product category is Microbiome Biotechnology. Its primary akta.pro industry code is HLAAAFAA, Live Biotherapeutic Products (LBPs), with a secondary code of HLAAAFAJ, Microbiome Manufacturing, Formulation & Delivery Technologies (encapsulation, spores, oral delivery). Its NAICS code is 325414 and its SIC code is 2836.